Product Introduction:
Capmatinib is an oral, selective MET inhibitor developed by Novartis. It was approved by the U.S. Food and Drug Administration (FDA) in May 2020 for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) with MET exon 14 skipping mutations (MET ex14). Capmatinib is the first targeted therapy for MET ex14 mutations.
The overall incidence of MET exon 14 skipping mutation in non-small cell lung cancer is 3%-6%, the incidence in lung adenocarcinoma is 3%-4%, and the incidence in lung sarcomatoid carcinoma can be as high as 22%. Patients carrying this mutation usually have a poor prognosis, are insensitive to chemotherapy, and have very unsatisfactory treatment. Capmatinib is a potent and selective MET inhibitor, and its ability to inhibit MET is much stronger than other MET targeted drugs such as crizotinib.
The study showed that the overall response rate of capmatinib was 67.9% and 40.6% in patients who had not received treatment and those who had previously received treatment (failure of one or two rounds of chemotherapy), respectively, and capmatinib provided durable responses in all patients: the median duration of response was 11.14 months in patients who had received the first treatment and 9.72 months in patients who had received the previous treatment.
Indications :
For the treatment of advanced non-small cell lung cancer (NSCLC) carrying MET gene exon 14 (MET ex14) skipping mutations
Usage and Dosage :
400 mg orally twice a day
